Objective:

The lack of an established treatment standard prompted an examination of whether kambakutaisoto, an herbal formula, is effective for non–rapid eye movement (NREM)–related parasomnias and night crying (provisionally defined as an infantile form of arousal parasomnia).

Methods:

This study included 137 children aged median 4.1 years (range, 0.02–18.5) who were admitted for hematological and oncological diseases.

Results:

Of 137, 3 children developed recurrent episodes of NREM-related parasomnias, and 3 developed night crying. The proportion of children with night-crying/parasomnia receiving invasive procedures was significantly higher than those without (100% vs. 47%, P = .013). All 6 children with night crying/parasomnia received kambakutaisoto at a dose of 0.13–0.22 g/kg per os and responded from the start of administration with a significant reduction in the number of episodes. No adverse effects were observed.

Conclusion:

Kambakutaisoto may be a safe and promising therapy for night crying and NREM-related parasomnias in children.

中文翻译：

---

Kambakutaisoto 治疗儿童因血液和肿瘤疾病长期住院期间出现的夜间哭闹和觉醒异态睡眠

客观的：

由于缺乏既定的治疗标准，人们开始研究 kambakutaisoto（一种草药配方）是否对非快速眼动 (NREM) 相关的睡眠异常和夜间哭泣（临时定义为唤醒性睡眠异常的婴儿形式）有效。

方法：

该研究包括 137 名中位年龄 4.1 岁（范围 0.02-18.5）的儿童，他们因血液和肿瘤疾病入院。

结果：

在 137 名儿童中，3 名儿童反复发作 NREM 相关的异态睡眠，3 名儿童出现夜间哭闹。夜间哭泣/睡眠异常的儿童接受侵入性手术的比例显着高于未接受侵入性手术的儿童（100% 对 47%，P = .013）。所有 6 名夜间哭泣/异态睡眠的儿童都接受了 kambakutaisoto，剂量为 0.13-0.22 g/kg per os，并且从给药开始就有反应，发作次数显着减少。没有观察到不良反应。

结论：

Kambakutaisoto 可能是治疗儿童夜间哭泣和 NREM 相关异态睡眠的一种安全且有希望的疗法。